$Jaguar Health (JAGX.US)$
Rare Disease Breakthrough? Jaguar's Drug Gets Double European Green Light

$Jaguar Health (JAGX.US)$
Jaguar Health's Cholera Drug Could Unlock $350M FDA Voucher as WHO Declares Emergency

$Jaguar Health (JAGX.US)$
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Tuesday, 18th February at 9:00 am
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million
1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide
SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ: ...

$Jaguar Health (JAGX.US)$ Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Accesswire· 4 mins ago
Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million
1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide

$Jaguar Health (JAGX.US)$
I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said. "We expect Magdalena's lead botanical drug candidate, MB2500, to soon be IND-enabled for one of the following indications: cognitive deficit in schizophrenia or executive ...

$Jaguar Health (JAGX.US)$
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Thursday, 6th February at 10:00 am
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026
SAN F...